The youngest patients, Gen Z, reported the highest rates (61%), followed by millennials (34%), Gen X (21%), and baby boomers (19%)
Our care team works directly with your insurer to secure approval, so you spend less time on paperwork and more time on your health
Remaining Scope for Side-Effect Improvement Retatrutide is a triple-action therapy that, like Lillys Mounjaro and Zepbound drugs, targets glucagon-like peptide-1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, while also acting on the glucagon receptor
Mechanistic analyses reveal glucagon receptor activation plays a crucial role through increased hepatic fatty acid oxidation and reduced de novo lipogenesis